Sinopharm Group Co (X2S) AI Stock Analysis

Sinopharm Group Co

(Frankfurt:X2S)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Distribution scaleThe company’s nationwide distribution footprint, purchasing scale, and coverage of hospitals, clinics, pharmacies, and other providers support a broad operating platform. These capabilities can reinforce customer reach and logistics efficiency, providing a durable foundation for recurring healthcare-product distribution activity.

Negative Factors

Revenue contractionThe recent reversal from earlier revenue growth to contraction signals weaker top-line momentum across the company’s distribution activities. If sustained, slower sales growth can limit operating leverage, reduce the scope for earnings expansion, and make future performance more dependent on efficiency improvements.

Sinopharm Group Co (X2S) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 6.27B
Dividend Yield: 4.27%
Average Volume (3M): 5,435
Price to Earnings (P/E): 6.1
Beta (1Y): 0.28
Revenue Growth: -4.46%
EPS Growth: 0.14%
Country: Germany
Employees: 94,910
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Distribution

Sinopharm Group Co Business Overview & Revenue Model

Company Description

Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are org...

Sinopharm Group Co Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:X2S against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:2192	71Outperform	HKD 4.67B	11.61	7.05%	4.98%	6.47%	8.10%
HK:2607	58Neutral	HKD 64.52B	11.88	6.64%	5.88%	9.12%	-3.22%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:2289	47Neutral	HKD 592.92M	10.81	7.70%	6.26%	14.25%	0.83%
HK:0673	39Underperform	HKD 360.66M	-5.29	-273.18%	―	5.52%	56.54%
HK:1931	26Underperform	HKD 575.63M	-6.45	-2.60%	―	-2.55%	-145.60%

* Healthcare Sector Average

Performance Comparison

DE:X2S and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:X2S	Sinopharm Group Co Class H	1.83	-0.20	-9.93%
HK:0673	China Health Group	0.26	-0.36	-58.06%
HK:2607	Shanghai Pharmaceuticals Holding Co Class H	11.11	-0.06	-0.53%
HK:1931	IVD Medical Holding Limited	0.35	-5.93	-94.35%
HK:2192	Medlive Technology Co., Ltd.	6.30	-4.03	-38.99%
HK:2289	Charmacy Pharmaceutical Co., Ltd. Class H	5.49	0.38	7.46%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Sinopharm Group Co AI Stock Analysis